Success Metrics

Clinical Success Rate
87.1%

Based on 135 completed trials

Completion Rate
87%(135/155)
Active Trials
0(0%)
Results Posted
85%(115 trials)
Terminated
20(13%)

Phase Distribution

Ph not_applicable
1
1%
Ph phase_1
42
27%
Ph phase_4
4
3%
Ph phase_3
82
53%
Ph phase_2
27
17%

Phase Distribution

42

Early Stage

27

Mid Stage

86

Late Stage

Phase Distribution156 total trials
Phase 1Safety & dosage
42(26.9%)
Phase 2Efficacy & side effects
27(17.3%)
Phase 3Large-scale testing
82(52.6%)
Phase 4Post-market surveillance
4(2.6%)
N/ANon-phased studies
1(0.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.5%

135 of 156 finished

Non-Completion Rate

13.5%

21 ended early

Currently Active

0

trials recruiting

Total Trials

156

all time

Status Distribution
Completed(135)
Terminated(21)

Detailed Status

Completed135
Terminated20
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
156
Active
0
Success Rate
87.1%
Most Advanced
Phase 4

Trials by Phase

Phase 142 (26.9%)
Phase 227 (17.3%)
Phase 382 (52.6%)
Phase 44 (2.6%)
N/A1 (0.6%)

Trials by Status

completed13587%
terminated2013%
withdrawn11%

Recent Activity

Clinical Trials (156)

Showing 20 of 156 trialsScroll for more
NCT01152255Phase 1

MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

Terminated
NCT00076973Phase 3

An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)

Completed
NCT00092807Phase 3

Sitosterolemia Extension Study (0653-003)(COMPLETED)

Completed
NCT00092820Phase 3

Sitosterolemia Extension Study (0653-004)(COMPLETED)

Completed
NCT00092885Phase 3

An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

Completed
NCT00092898Phase 3

An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)

Completed
NCT00140907Phase 4

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

Completed
NCT00092105Phase 3

Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)

Completed
NCT00140881Phase 4

A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)

Completed
NCT00101439Phase 3

A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)

Completed
NCT00812006Phase 3

A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

Completed
NCT00739050Phase 4

Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)

Terminated
NCT00092677Phase 3

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

Completed
NCT00276458Phase 3

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)

Completed
NCT00894556Phase 3

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Completed
NCT00284856Phase 3

Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)

Completed
NCT00739297Phase 1

The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)

Completed
NCT00516737Phase 3

Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)

Completed
NCT00943852Phase 1

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Completed
NCT00963599Phase 3

Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
156